Lilly rides wave of weight-loss drug demand, working to expand capacity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Eli Lilly (LLY) beats profit forecast amid soaring weight-loss drug demand
February 6, 2024 6:58 AM EST(Updated - February 6, 2024 8:26 AM EST)
Investing.com -- Eli Lilly (NYSE: LLY) has reported fourth-quarter revenue that topped estimates thanks in large part to soaring demand for its weekly diabetes injection.
The U.S. drugmaker's treatment -- branded as Mounjaro -- is in a race with a rival version from Denmark's Novo Nordisk to... More
